Delphinus Medical Technologies has promoted Scott White to president and CEO. He replaces Mark Forchette, who is retiring.

White joined Delphinus earlier this year as chief commercial officer. At the time, the company charged him with leading commercialization efforts for its 3D whole breast ultrasound tomography system SoftVue.

Forchette had served as Delphinus’ CEO since 2014. On LinkedIn, he discussed his pending retirement and noted that he “had the opportunity to lead an amazing team, deliver a breakthrough technology to benefit patients… and save lives through commercial implementation.”

The Food and Drug Administration approved SoftVue paired with mammography for screening in October 2021. Delphinus claims that SoftVue can identify up to 20% more cancers than mammography alone.

White said in a statement that he was “incredibly thankful for the opportunity to lead the Delphinus team into the future.”

“The Delphinus SoftVue system is unlike any other technology in the market today, and we believe it is the answer to the dense breast screening challenge that currently exists for tens of millions of women,” he added in the statement. 

Before he arrived at Delphinus, White was chief commercial officer at Hyperfine, maker of a bedside neurological MRI platform. During his 25-year career in commercial and finance leadership, he has also served as VP of global sales at Rapid Micro Biosystems and as area VP at Intuitive Surgical.

Under White’s leadership, Delphinus plans to expand commercialization of SoftVue. The company also hopes to bolster its commercial infrastructure by building up dense-breast screening programs in targeted areas.

“Scott is a proven leader and shares my passion that SoftVue is the solution to address the unmet needs of dense breast screening patients,” Forchette said in the statement. “The board and I are confident that he will lead the company into a very successful future.”

The leadership succession comes a few months after Delphinus secured $12 million in growth capital from Trinity Capital, which the company will use to expand its footprint. At the time, Forchette noted that the funding would help the company “make impactful investments to help sites embrace this innovation and serve the unmet patient needs that SoftVue was designed to address.”